Clinical Endocrinology: Challenges and Improvements

The metabolism of T3 and T4 combination therapy into active and inactive intermediates involves the action of 3 types of deiodinases. Recent studies of common genetic variations in deiodinase and thyroid hormone transport proteins offer fresh insights in understanding the variable response to thyroid hormone therapy and future research may clarify whether subsets of patients will benefit from challenges and improvements to combination therapy. Despite significant challenges, opportunities abound for improving the Thyroid Treatment Augments Psychiatric Therapy and also Improvements of Reproductive, Neuro-endocrinology or Neuroendocrine Function in Hypothalamic.

  • T3 & T4 combination therapy
  • Challenges and improvements to combination therapy
  • Vitamin D deficiency and management guidelines
  • Thyroid hormone receptors and independent signalling in brain
  • Noncompliance With Medical Treatment
  • Improvements of Reproductive, Neuroendocrine Function in Hypothalamic Amenorrhea
  • T3 Treatment Augments Psychiatric Therapy

Related Conference of Clinical Endocrinology: Challenges and Improvements

September 09-10, 2024

33rd International Diabetes and Healthcare Conference

Paris, France
September 09-10, 2024

7th Annual Meeting on Diabetes and Endocrinology

Paris, France
September 09-10, 2024

4th European Endocrinology and Diabetes Congress

Paris, France
September 25-26, 2024

5th World Summit on Diabetes Expo

Rome, Italy
October 14-15, 2024

3rd International Summit on Hormonal Disorders

Madrid, Spain
November 22-23, 2024

20th World Congress on Endocrinology & Diabetes

Amsterdam, Netherlands

Clinical Endocrinology: Challenges and Improvements Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in